Key facts
- Cephagenix’s last known valuation is $6.2M (Sep 2025).
- It has raised $2.7M; the latest was Seed Round ($2.7M) in Sep 2025.
- Notable investors include AbbVie Ventures, AdBio partners, JOHealth, Saniona.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Cephagenix
- ·The full record, as it builds
Funding rounds
No funding rounds for Cephagenix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cephagenix
Developer of migraine treatments intended to address the underlying mechanisms of the condition. The company focuses on identifying and developing selective inhibitors of the adenosine triphosphate-sensitive potassium channel subtype expressed in intracranial arteries, with compounds demonstrating efficacy in preclinical migraine models, enabling individuals suffering from migraine to develop treatments through targeted and mechanism-based therapies.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2020
- Website
- cephagenix.com/
- Ownership
- Privately Held (backing)
Cephagenix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cephagenix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cephagenix in its N-PORT filings yet. We sweep new filings monthly.